Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference
Fulcrum Therapeutics (Nasdaq: FULC) announced its participation in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 12, 2022, at 11:20 a.m. PT (2:20 p.m. ET).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC) announced its participation in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 12, 2022, at 11:20 a.m. PT (2:20 p.m. ET). A live audio webcast will be available on Fulcrum’s Investor Relations page, with an archived replay for 30 days. Fulcrum specializes in developing treatments for genetically defined rare diseases, with lead programs including losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease and beta-thalassemia, leveraging their proprietary FulcrumSeek™ product engine.
Details
News Market Reaction – FULC
The recorded move for FULC in the trading session of this news was -7.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference, on Thursday, May 12, 2022 at 11:20 a.m. PT (2:20 p.m. ET).
A live audio webcast will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 30 days.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter @FulcrumTx and LinkedIn.
Contact:
Investors:
Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
212-362-1200
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.